Mission Moment – Dr. Carl June’s Research Deemed Breakthrough Therapy by FDA We learned exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy that LLS has played a significant role in helping to advance. The therapy, CTL019, also known as chimeric antigen receptor (CAR) therapy, is an approach that genetically engineers patients’ immune T cells and reintroduces them into the body to kill cancer cells. The work is being led by Carl June, M.D., at University of Pennsylvania, who, along with his team, LLS has been funding for more than 16 years with a commitment of more than $21 million through 2017. Check out the film!
P.S. Don’t forget to donate to the cause: http://pages.teamintraining.org/gba/nikesf14/ashbo